Thyroid Cancer Clinical Trials

82 recruiting

Thyroid Cancer Trials at a Glance

131 actively recruiting trials for thyroid cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 31 trials, with the heaviest enrollment activity in Houston, Shanghai, and Beijing. Lead sponsors running thyroid cancer studies include Fudan University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and M.D. Anderson Cancer Center.

Browse thyroid cancer trials by phase

Treatments under study

About Thyroid Cancer Clinical Trials

Looking for clinical trials for Thyroid Cancer? There are currently 82 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 131 trials

Recruiting

Studies on Tumors of the Thyroid

Thyroid CancerPapillary Thyroid CancerFollicular Thyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,500 enrolled1 locationNCT00001160
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Non-Medullary Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)500 enrolled1 locationNCT01109420
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Thyroid CancerThyroidRefractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center100 enrolled1 locationNCT05733013
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaThyroid CancerGlioma
Pfizer124 enrolled77 locationsNCT05538130
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 2

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Metastic Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)54 enrolled1 locationNCT04927416
Recruiting
Phase 2

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled1 locationNCT03841617
Recruiting
Phase 2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Thyroid Cancer
Thomas Hope62 enrolled1 locationNCT06961084
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2

Pembrolizumab in High-risk Thyroid Cancer

Differentiated Thyroid Cancer
Istituti Clinici Scientifici Maugeri SpA25 enrolled1 locationNCT05852223
Recruiting

New MRI Biomarkers in Head and Neck Cancers

Head and Neck CancerThyroid Cancer
Memorial Sloan Kettering Cancer Center200 enrolled1 locationNCT03483337
Recruiting
Phase 2

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

CancerPediatric CancerDifferentiated Thyroid Cancer+1 more
Children's Hospital of Philadelphia13 enrolled4 locationsNCT06458036
Recruiting

Natural History Study of Parathyroid Disorders

Primary HyperparathyroidismParathyroid CancerPseudohypoparathyroidism+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3,000 enrolled1 locationNCT04969926
Recruiting
Not Applicable

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Pancreatic Neuroendocrine TumorMedullary Thyroid CancerAdrenal Cortical Carcinoma+1 more
Shanghai Jiao Tong University School of Medicine21 enrolled1 locationNCT06141369
Recruiting
Not Applicable

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

Cultural AdaptationMedullary Thyroid Cancer (MTC)
M.D. Anderson Cancer Center40 enrolled1 locationNCT07142005
Recruiting

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Medullary Thyroid Cancer
National Cancer Institute (NCI)259 enrolled1 locationNCT01660984